ClinicalTrials.gg
CompletedNCT01028222TEAMUpdated Dec 30, 2015Results posted

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

A Phase 2 interventional study of Nilotinib and DTIC in Melanoma, sponsored by Novartis Pharmaceuticals. Completed at 49 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Melanoma by Novartis — 1 open to participants now, 6 under way, none of them phase 3. Melanoma · Novartis.

Enrollment
30th of 35
55 · median 134
Started
2010
with 1 other
Phase 2
10 of 51
none open now
Registered
7th of 51
by date

Among the 51 studies in Melanoma by Novartis, this one is the 30th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2010, is one of 10 in phase 2, and was the 7th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 51 studies in Melanoma by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Melanoma by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.

Read the detailed description

This trial began as a multi-center, randomized, Phase III, controlled trial for nilotinib vs (DTIC) dacarbazine to assess the efficacy and safety of nilotinib (400 mg bid) in patients with c-Kit mutated metastatic and/or inoperable melanoma. The study was open to patients with mucosal or acral melanoma.

Due to substantial difficulties identifying and recruiting eligible patients, the trial design was altered from a randomized, two-arm, Phase III study to a single-arm, Simon two-stage Phase II study with protocol Amendment 2 (27-Jul-2011). While the original protocol required the recruitment of 120 patients, this amendment required the study to recruit only 41 patients (patients randomized to nilotinib prior to Amendment 2 were to be counted in this total, but those randomized to dacarbazine ( DTIC ) DTIC were not). Patients randomized to DTIC were allowed to cross-over to nilotinib, either immediately or at the time of progression.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Melanoma
  • AMN107
  • c-Kit
  • c-Kit mutated metastatic and/or inoperable melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed mucosal or acral 2. Presence of a c-Kit mutation of exon 9, 11 or 13, or mutations Y822D and mutations D820Y, Y823D of exon 17, as confirmed by the central laboratory 3. Stage III unresectable or stage IV disease 4. The presence of one or more as detected by radiological or photographic methods and assessed according to 1.0. Lesions must have a size of at least 10mm at longest diameter (using a slice thickness of 5 mm)or double the slice thickness to be considered a target lesion. Target lesions should not be selected in previously irradiated fields unless there is clear evidence of progression 5. 0 - 2

Exclusion criteria

Exclusion Criteria:

  1. C-Kit mutation of exons 17(except mutations D820Y, Y822D or Y823D) or any other exon not allowed by the inclusion criteria
  2. Patients with c-Kit amplifications only and no mutation
  3. Patients with any history of
  4. Patients who have had any prior treatment with TKIs
  5. Patients receiving medications or herbal extracts which interfere with nilotinib metabolism which are not discontinued by the time of the baseline visit
  6. Acute or chronic liver or renal disease considered unrelated to melanoma

Other protocol-defined inclusion/exclusion criteria may have applied.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Nilotinib

    400 mg twice daily

    Drug: Nilotinib

  • Active comparator
    DTIC

    850 mg/m2 IV every 3 weeks

    Drug: DTIC

Interventions

  • Nilotinib was provided as 200 mg hard gelatin capsules for oral use.

    Also known as: AMN107

  • DrugDTIC

    DTIC was supplied locally as sterile powder for i.v. infusion.

    Also known as: Dacarbazine

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the proportion of participants with a best overall response (BOR) of a confirmed complete response or partial response (CR+PR) determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.

    Time frame: End of study (up to 39 months)

Secondary outcomes

  1. Durable Overall Response Rate (DORR)

    DORR was defined as the rate of best overall response (CR+PR) lasting at least 12 weeks determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). The duration of ORR responders is computed from the date of first documented response (CR/PR) to the date of first documented progression or death due to underlying disease. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.

    Time frame: End of study (up to 39 months)

  2. Progression Free Survival (PFS)

    PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a \>=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.

    Time frame: End of study (up to 39 months)

  3. Overall Survival (OS)

    OS was defined as the time from the date of the start of treatment to the date of death due to any cause.

    Time frame: End of study (up to 39 months)

  4. Time to Objective Response (TOR)

    TOR was defined as the time between the start date of treatment until first documented confirmed response of CR or PR determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.

    Time frame: End of study (up to 39 months)

  5. Disease Control Rate (DCR)

    DCR was defined as the proportion of participants with an overall response of CR of any duration, PR of any duration, or stable disease (SD) for a minimum of 12 weeks from start of treatment. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions; PD, a \>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; SD: no change or small changes that do not meet previously given criteria for CR, PR or PD.

    Time frame: End of study (up to 39 months)

  6. PFS Rate

    PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a \>=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.

    Time frame: End of study (up to 39 months)

  7. OS Rate

    OS was defined as the time from the date of the start of treatment to the date of death due to any cause.

    Time frame: End of study (up to 39 months)

07

Results

Posted Nov 26, 2015

Participant flow

Participant flow — Overall Study
MilestoneNilotinibDTIC
Started4213
Cross over from dtic to nilotinib010
Completed40
Not completed3813
Withdrew: Protocol deviation10
Withdrew: Disease progression339
Withdrew: Administrative problems11
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject10
Withdrew: Crossover to nilotinib w/out progression02
Withdrew: Adverse event20

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR was defined as the proportion of participants with a best overall response (BOR) of a confirmed complete response or partial response (CR+PR) determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.0) based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.

Time frame:
End of study (up to 39 months)
Reported as:
Number · Participants
Overall Response Rate (ORR)
ParticipantsNilotinibDTIC
Overall Response Rate (ORR)113
SecondaryDurable Overall Response Rate (DORR)

DORR was defined as the rate of best overall response (CR+PR) lasting at least 12 weeks determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). The duration of ORR responders is computed from the date of first documented response (CR/PR) to the date of first documented progression or death due to underlying disease. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no worsening of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.

Time frame:
End of study (up to 39 months)
Reported as:
Number · Participants
Durable Overall Response Rate (DORR)
ParticipantsNilotinibDTIC
Durable Overall Response Rate (DORR)113
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a \>=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.

Time frame:
End of study (up to 39 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsNilotinibDTIC
Progression Free Survival (PFS)4.2 (2.1 to 5.8)4.2 (0.8 to 8.0)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the start of treatment to the date of death due to any cause.

Time frame:
End of study (up to 39 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsNilotinibDTIC
Overall Survival (OS)18.0 (10.9 to 20.3)22.8 (4.9 to NA)
SecondaryTime to Objective Response (TOR)

TOR was defined as the time between the start date of treatment until first documented confirmed response of CR or PR determined by RECIST v1.0 based on local investigators' assessment (CT/MRI/photography). Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions. For CR or PR, tumor measurements must be confirmed by 2nd assessments at least 4 weeks apart.

Time frame:
End of study (up to 39 months)
Reported as:
Median · months
Time to Objective Response (TOR)
monthsNilotinibDTIC
Time to Objective Response (TOR)NA (NA to NA)NA (NA to NA)
SecondaryDisease Control Rate (DCR)

DCR was defined as the proportion of participants with an overall response of CR of any duration, PR of any duration, or stable disease (SD) for a minimum of 12 weeks from start of treatment. Per RECIST, CR: disappearance of all target lesions, all non-target lesions, and no new lesion; PR: a \>=30% decrease in the sum of the longest dimensions of the target lesions (TLs) taking as a reference the baseline sum, no unequivocal progression of non-TLs, and no new lesions; PD, a \>=20% increase in TLs, clearly worsening of non-TLs, or emergence of new lesions; SD: no change or small changes that do not meet previously given criteria for CR, PR or PD.

Time frame:
End of study (up to 39 months)
Reported as:
Number · Participants
Disease Control Rate (DCR)
ParticipantsNilotinibDTIC
Disease Control Rate (DCR)207
SecondaryPFS Rate

PFS was defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. Progression is defined using RECIST v1.0, as a \>=20% increase in the sum of longest diameter of all target lesions, from smallest sum of longest diameter of all target lesions recorded at or after baseline; or a new lesion; or unequivocal progression of non-target lesions.

Time frame:
End of study (up to 39 months)
Reported as:
Number · Percentage of participants
PFS Rate
Percentage of participantsNilotinibDTIC
PFS Rate34.623.1
SecondaryOS Rate

OS was defined as the time from the date of the start of treatment to the date of death due to any cause.

Time frame:
End of study (up to 39 months)
Reported as:
Number · Percentage of participants
OS Rate
Percentage of participantsNilotinibDTIC
OS Rate63.666.7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib—12/42 (28.6%)40/42 (95.2%)
DTIC—1/13 (7.7%)9/13 (69.2%)
Crossover Nilotinib Treatment—4/10 (40%)10/10 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventNilotinibDTICCrossover Nilotinib Treatment
ArrhythmiaCardiac disorders0/420/131/10
Myocardial infarctionCardiac disorders0/420/131/10
Retinal detachmentEye disorders0/420/131/10
Abdominal painGastrointestinal disorders2/420/131/10
AscitesGastrointestinal disorders0/420/131/10
General physical health deteriorationGeneral disorders0/420/131/10
Oedema peripheralGeneral disorders0/420/131/10
Herpes zoster cutaneous disseminatedInfections and infestations0/420/131/10
InfectionInfections and infestations0/420/131/10
HyperglycaemiaMetabolism and nutrition disorders0/420/131/10
Most frequent other events
Showing 10 of 128
Most frequent other events
EventNilotinibDTICCrossover Nilotinib Treatment
RashSkin and subcutaneous tissue disorders20/422/133/10
Blood bilirubin increasedInvestigations19/421/133/10
NauseaGastrointestinal disorders18/425/132/10
FatigueGeneral disorders13/425/134/10
HeadacheNervous system disorders6/425/133/10
Decreased appetiteMetabolism and nutrition disorders13/422/133/10
DiarrhoeaGastrointestinal disorders7/421/133/10
AstheniaGeneral disorders2/421/133/10
HyperglycaemiaMetabolism and nutrition disorders9/421/133/10
CoughRespiratory, thoracic and mediastinal disorders9/422/133/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NilotinibDTICTotal
Mean64.7 ± 12.3968.8 ± 12.9966.8 ± 12.69
Sex: Female, Male
Sex: Female, Male(Participants)NilotinibDTICTotal
Female23831
Male19524
08

Study locations

49 sites
  • City of Hope National Medical Center City of Hope national Med Ctr
    Duarte, California 91010-3000, United States
  • University of California San Diego - Moores Cancer Center UCSD Moores Cancer Center
    La Jolla, California 92093-0658, United States
  • University of California at Los Angeles UCLA
    Los Angeles, California 90024, United States
  • California Pacific Medical Center California Pacific Med
    San Francisco, California 94120-7999, United States
  • University of Colorado Univ Colorado 2
    Aurora, Colorado 80045, United States
  • Rush University Medical Center SC
    Chicago, Illinois 60612, United States
  • Oncology Specialists, SC Dept.of Oncology Specialists
    Park Ridge, Illinois 60068-0736, United States
  • Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Medical Oncology
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute DFCI - Brookline
    Boston, Massachusetts 02215, United States
  • Mayo Clinic - Rochester Mayo Clinic- Gonda
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine CAMN107B2301
    St. Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Case Western Reserve Case Western
    Cleveland, Ohio 44106-5000, United States
  • Baylor Health Care System/Sammons Cancer Center Baylor 2
    Dallas, Texas 75246, United States
  • Novartis Investigative Site
    Buenos Aires, C1125ABE, Argentina
  • Novartis Investigative Site
    North Sydney, New South Wales 2060, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    East Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Brussel, 1090, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Belo Horizonte, MG 30150-281, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20230-130, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01246-000, Brazil
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 1Z5, Canada
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Köln, 50937, Germany
  • Novartis Investigative Site
    Muenchen, 80336, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Meldola, FC 47014, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milano, MI 20133, Italy
  • Novartis Investigative Site
    Milano, MI 20141, Italy
  • Novartis Investigative Site
    Padova, PD 35100, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
  • Novartis Investigative Site
    Singapore, 169610, Singapore
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Hospitalet de LLobregat, Cataluña 08907, Spain
  • Novartis Investigative Site
    Goteborg, SE-413 45, Sweden
  • Novartis Investigative Site
    Malmö, SE-205 02, Sweden
  • Novartis Investigative Site
    Stockholm, SE-171 76, Sweden
  • Novartis Investigative Site
    Uppsala, SE-751 85, Sweden
  • Novartis Investigative Site
    Zürich, 8091, Switzerland
09

References and documents

Publications

  • Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017 Jun 1;28(6):1380-1387. doi: 10.1093/annonc/mdx079. PubMed 28327988 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2009
First posted
Dec 9, 2009
Start
Jun 2010
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Nov 26, 2015
Last update
Dec 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01028222
Responsible party
Sponsor
First posted
Dec 9, 2009
Start date
Jun 2010
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Nov 26, 2015
Last update
Dec 30, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion